Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mila Ju

Vascular Surgery Allentown, PA Medical Doctor

NPI 1629207352 CMS profile 1150035

1259 S Cedar Crest Blvd, Suite 301, Allentown, PA 18103

Open in the dashboard

General payments

$35,667

95 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mila Ju of Allentown, PA is reported in the CMS Open Payments database as having received $35,667 across 95 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $227 4
2024 General $144 1
2023 General $356 4
2022 General $18,842 30
2021 General $1,154 9
2020 General $2,609 7
2019 General $12,335 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mila Ju
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Mila Ju were reported at $227. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Mila Ju Vascular Surgery median Middle half National median
2019 $12,335 $796 $226–$2,363 $163
2020 $2,609 $348 $118–$1,110 $114
2021 $1,154 $471 $158–$1,421 $132
2022 $18,842 $725 $222–$2,183 $149
2023 $356 $836 $257–$2,440 $160
2024 $144 $909 $252–$2,619 $164
2025 $227 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $33,663 71 payments
  2. W. L. Gore & Associates, Inc. $651 6 payments
  3. Medtronic, Inc. $455 4 payments
  4. Medtronic USA, Inc. $229 2 payments
  5. Medtronic Vascular, Inc. $190 2 payments
  6. Cook Medical LLC $189 3 payments
  7. Shockwave Medical, Inc $137 1 payment
  8. Boston Scientific Corporation $52 2 payments
  9. KCI USA, Inc $38 1 payment
  10. Molnlycke Health Care US, LLC $23 1 payment
  11. Other $38 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $23,850 10 payments
  2. Travel and Lodging $7,983 38 payments
  3. Food and Beverage $3,835 47 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $19,627 34 payments
  2. ENROUTE Transcarotid Stent $19,627 34 payments
  3. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $14,036 37 payments
  4. ENROUTE Transcarotid Stent System $14,036 37 payments
  5. ENHANCE Transcarotid Peripheral Access Kit Carotid Artery Disease $14,036 37 payments
  6. ENROUTE 0.014 Guidewire $14,036 37 payments
  7. ENHANCE Transcarotid Peripheral Access Kit Cardiology/Vascular Diseases $937 6 payments
  8. ENROUTE .014 Guidewire $937 6 payments
  9. ENDURANT IIS $276 2 payments
  10. PROPATEN Vascular Graft $237 2 payments
  11. Other $1,639 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

395

Median for Vascular Surgery: 122

Drug cost

$115,396

Median for Vascular Surgery: $14,135

Branded share of claims

72.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 66 $66,816
Eliquis Apixaban Brand 36 $43,067
Cilostazol Generic 94 $2,786
Clopidogrel Clopidogrel Bisulfate Brand 186 $2,677
Prednisone Generic 13 $51

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$156,448

Medicare's payments for the services billed

Medicare patients

744

Average age 75

Services billed

1,526

282 women, 462 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 55%
Chronic kidney disease 47%
Diabetes 43%
Heart failure 36%
COPD 33%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

95 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record